Clinical Trials Logo

Clinical Trial Summary

Asian Flushing Syndrome (AFS) is a genetic disease affecting approximately 70% of patients of East Asian descent characterized by severe flushing with minimal ethanol consumption. This reaction is cosmetically unattractive and socially limiting. Many Asian patients avoid drinking alcohol on dates, at weddings, and during business events because of this reaction and the perception of being drunk or alcoholic.

Ethanol is normally metabolized to acetic acid by two enzymes. The first enzyme, alcohol dehydrogenase (ADH) converts ethanol to acetaldehyde. The second enzyme, aldehyde dehydrogenase 2 (ALDH2) converts the toxic acetaldehyde to harmless acetic acid. When ADH function is increased or ALDH2 function is decreased, the toxic intermediate acetaldehyde accumulates resulting in cutaneous flushing. Over 70% of East Asians have genetic polymorphisms in either ADH or ALDH2 leading to intense flushing with ethanol consumption.

There are no effective topical treatments for the Asian Flushing Syndrome. Oral antihistamines have been used with some success in treating symptoms of Asian Flushing Syndrome; however these can have sedating effects and may be dangerous in combination with alcohol.

Brimonidine is a selective α2-adrenoceptor agonist that acts through vasoconstriction and is commercially available in a topical gel. This topical treatment is FDA approved for the indication of facial flushing and has a long history of safety in human subjects.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT03497442
Study type Interventional
Source University of California, San Francisco
Contact Trial Coordinator
Phone (415) 353-9684
Status Recruiting
Phase Early Phase 1
Start date July 12, 2018
Completion date March 2019

See also
  Status Clinical Trial Phase
Recruiting NCT03340051 - Remote Alcohol Monitoring and Episodic Thinking N/A
Recruiting NCT02829970 - Helping College Students With ADHD Lead Healthier Lifestyles N/A
Completed NCT02388243 - The Computer-based Drug and Alcohol Training Assessment in Kenya N/A
Completed NCT00248612 - Psychosocial and Medication Treatment for Anxiety in Alcoholism Phase 2/Phase 3
Recruiting NCT03535129 - A Response Modulation Hypothesis of Socioemotional Processing Associated With Alcohol Use Disorder
Completed NCT00142844 - Combination of Disulfiram Plus Naltrexone to Treat Both Cocaine- and Alcohol-dependent Individuals - 1 Phase 2
Completed NCT00000257 - Effects of Alcohol History on Effects of Nitrous Oxide - 9 N/A
Completed NCT00000278 - Disulfiram for Cocaine-Alcohol Abuse - 3 Phase 2
Recruiting NCT02655354 - A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity N/A
Completed NCT01344122 - Medication-Assisted Treatment Implementation in Community Correctional Environments (MATICCE) N/A
Completed NCT01227980 - Corticotropin-Releasing Hormone Receptor 1 (CRH1) Antagonism in Anxious Alcoholics^ Phase 2
Completed NCT00400010 - Alcohol Expert System Intervention for Problematic Alcohol Use N/A
Completed NCT00391742 - Stepped Interventions for Problem Drinkers N/A
Completed NCT02968186 - Implementing Screening and Brief Interventions for Excessive Drinkers in Primary Health Care N/A
Completed NCT01847183 - Evaluation of an School-based Alcohol Prevention Program for Middle School Students Phase 2
Completed NCT00000261 - Effects of Alcohol History on Effects of Sevoflurane and Nitrous Oxide - 13 Phase 2
Not yet recruiting NCT03695653 - Messaging Interventions to Reduce Alcohol Problems Project N/A
Completed NCT02797990 - Conflict Between Maternal Autonomy and Child Health in Substance-use N/A
Completed NCT01631630 - Piogliatazone for Alcohol Craving Phase 2
Completed NCT01642381 - Component Analysis for Motivational Interviewing N/A